Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan

Journal of the College of Physicians and Surgeons Pakistan

Volumn 19, Issue 2, 2009, Pages 99-103

  Sharif, Muhammad Ashraf ^a,b   Mamoon, Nadira ^a   Mushtaq, Sajid ^a   Khadim, Muhammad Tahir ^a  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (Pakistan)

^b NONE   (Pakistan)

Author keywords

Breast carcinoma; Estrogen receptor; HER 2 neu; Progesterone receptor; Tumour marker

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CROSS-SECTIONAL STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; OBSERVATIONAL STUDY; PAKISTAN; PARTIAL MASTECTOMY; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOLOGIC FACTORS; INDICATORS AND REAGENTS; LYMPHATIC METASTASIS; MIDDLE AGED; PAKISTAN; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; STREPTAVIDIN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 64149125020     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-6.
2. Belkacémi Y, Penault-Llorca F, Gligorov J, Azria D. The use of breast cancer subtype classification to predict local and distant recurrence: a review. Cancer Radiother 2008; 12:577-83.
3. Rastelli F, Crispino S. Factors predictive of response to hormone therapy in breast cancer. Tumouri 2008; 94:370-83.
4. Al-Dujaily EA, Al-Janabi AA, Pierscionek T, Yasseen AA. High prevalence of HER-2/neu overexpression in female breast cancer among an Iraqi population exposed to depleted uranium. J Carcinog 2008; 7:8.
5. Andre F, Broglio K, Roche H, Martin M, Mackey JR, Penault-Llorca F, et al. Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. J Clin Oncol 2008; 26:2636-43.
6. Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B. Expression of HER2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone. Anticancer Res 2005; 25:1719-23.
7. Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, et al. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumour xenografts. Cancer Res 2008; 68: 7493-501.
8. Ahmed N. Breast carcinoma in Pakistani women: how it differs from the West. J Surg 1991; 2:56-8.
9. Malik IA, Mushtaq S, Khan AH, Mamoon N, Afzal S, Jamal S, et al. A morphological study of 280 mastectomy specimens of breast carcinoma. Pak J Pathol 1994; 5:5-8.
10. Siddiqui M, Kayani N, Sulaiman S, Hussainy A, Shah S, Muzaffar S. Breast carcinoma in Pakistani females: a morphological study of 572 breast specimens. J Pak Med Assoc 2000; 50:174-7.
11. Fatima S, Faridi N, Gill S. Breast cancer: steroid receptors and other prognostic indicators. J Coll Physicians Surg Pak 2005; 15: 230-3.
12. Siddiqui T, Khan S, Kayani N, Salam A, Kiran S, Jilani S. The clinical pattern of HER-2/neu oncogene overexpressing breast cancer in Pakistani patients at initial presentation: an analysis of HER-2/neu positive versus negative disease: a preliminary report. J Pak Med Assoc 1999; 49:294-7.
13. Stewart BW, Kleihues P, editors. Breast cancer. In: World cancer report. World Health Organisation; international agency for research on cancer. Lyon: IARC Ness; 2003:p.183-93.
14. Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 2005; 123: 541-6.
15. Park JW, Neve RM, Szollosi J, Benz CC: Unraveling the biologic and clinical complexities of HER-2. Clin Breast Cancer 2008; 8: 392-401.
16. Siddiqui MS, Kayani N, Pervez S, Muzaffar S, Aziz SA, Setna Z, et al. Breast diseases: histopathological analysis of 3279 cases at a tertiary care centre in Pakistan. J Pak Med Assoc 2003: 53; 94-7.
17. Wahid Y, Mushtaq S, Khan AH, Malik IA, Mamoon N. A morphological study of prognostic features in carcinoma breast. Pak J Pathol 1998; 9:9-13.
18. Aryandono T, Harijadi, Ghozali A. Correlation of clinical, pathological status, hormone receptor and c-erbB-2 oncoprotein in breast cancer patients. Ann Oncol 2005; 16:1755-61.
19. Almasri NM, Al-Hamad M. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Res 2005: 7; R598-604.
20. Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, et al. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol 2005; 58:611-6.
21. Naqvi SQ, Abbas R, Jamal Q, Mahmood RK. Immunohistochemical determination of HER-2/neu overexpression in invasive ductal carcinoma of breast with cervical nodal metastasis. Pak J Otolaryngol 2002; 18:29-31.
22. Traina A, Agostara B, Marasà L, Calabrò M, Zarcone M, Carruba G. HER-2/neu expression in relation to clinicopathologic features of breast cancer patients. Ann N Y Acad Sci 2006; 1089:159-67.
23. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldin MT, Bufalino R, et al. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 1991; 49:44-9.
24. Ayadi L, Khabir A, Amouri H, Karray S, Dammak A, Guermazi M, et al. Correlation of HER-2 overexpression with clinicopathological parameters in Tunisian breast carcinoma. World J Surg Oncol 2008; 6:112.
25. Hoff ER, Tubbs RR, Myles JL, Procop GW. HER-2/neu amplification in breast cancer: stratification by tumor type and grade. Am J Clin Pathol 2002; 117:916-21.
26. Al-Ahwal MS. HER-2 positivity and correlation with other histopathologic features in breast cancer patients - hospital based study. J Pak Med Assoc 2006; 56:65-8.
27. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7,016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol 2000; 53:688-96.